Login Get Started
Browse
Shares
Healthcare
Healthcare Equipment & Supplies
Fluoguide AS
Fluoguide AS logo

FLUO TO1 - Fluoguide AS Reuters News

DKK13.2 0.0  0.0%

Last Trade - 05/05/20

Sector
Healthcare
RiskRating
Highly Speculative
Size
Small Cap
Style
Market Cap £78.3m
Enterprise Value £77.1m
Revenue £n/a
Position in Universe th / 1850
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions FLUO TO1 Dividends
Reuters News
All News Reuters News Company Announcements
BRIEF-Fluoguide Announces Approval For Listing On Nasdaq First North Growth Market Sweden On 24 Feb.
5th Feb News
BRIEF-Fluoguide Plans To Change Listing Venue
3rd Feb News
BRIEF-Fluoguide Annonces Publication Of 2 Patent Applications Covering Co's uPAR Technology Platform For Improving Surgery
2nd Feb News
BRIEF-Fluoguide Q4 Operating Loss DKK 8.5 Mln
26th Jan News
BRIEF-Fluoguide Q4 Operating Loss Widens To DKK 8.5 Mln
26th Jan News
BRIEF-Fluoguide Awarded DKK 1.2 Mln By Innovation Fund Denmark
26th Oct '20 News
BRIEF-FluoGuide Appoints Henrik Moltke As CFO
21st Sep '20 News
BRIEF-FluoGuide Q2 Operating Loss Widens To Was DKK 6.6 Mln
14th Aug '20 News
BRIEF-Fluoguide And LI-COR Biosciences Sign Agreement
13th Aug '20 News
BRIEF-FluoGuide Awarded EUR 2.5 million By The European Innovation Council
9th Jun '20 News
BRIEF-Fluoguide Q1 Operating Result Was KDKK-3,923
29th May '20 News
BRIEF-FluoGuide Gets About DKK 6.4 Mln Through Warrant Exercise
12th May '20 News
BRIEF-FluoGuide Signs Agreement With Rigshospitalet And University Of Copenhagen
23rd Apr '20 News
BRIEF-Fluoguide Shortlisted For EU Grant
24th Mar '20 News
BRIEF-Fluoguide Proposes Directed Share Issue To Strengthen Its Ownership
30th Jan '20 News
BRIEF-FluoGuide Gets Patent In Europe
7th Jan '20 News
BRIEF-Fluoguide Q1 Operating Loss Widens To DKK 442,000
31st May '19 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.